In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase 2-3 study evaluated the combination of relatlimab (anti LAG-3) and nivolumab […]
The risk of locoregional and distance recurrence of cutaneous melanoma in stage IIB/IIC is high and there is limited evidence on the clinical benefit of adjuvant […]
Establishing the association of immunotherapy with spermatogenesis is an essential step for the preservation of male fertility A research letter published in JAMA Oncology recently discussed […]
The analysis was performed in an oncology setting of the American community Real-world results of adjuvant treatment of melanoma in an American community oncology setting were […]
Update data on recurrence-free survival were evaluated in the OpACIN and OpACIN-neo trials, which were presented at AACR 2020 Update data on 36- and 18-month recurrence-free […]
Experts released two important studies on the use of targeted therapy and immunotherapy in the metastatic melanoma scenario During the virtual presentation of the AACR (American […]